Fatemeh Hajirezaei1, Sayyed Mohammad Hossein Ghaderian2,3, Mandana Hasanzad1, Mohsen Nafar4, Mohammad Hasan Ghadiani5, Sajjad Biglari6, Nasim Sohrabifar2, Hossein Jafari6. 1. Islamic Azad University, Tehran Medical Branch, Tehran, Iran. 2. Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 3. Urogenital Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 4. Chronic kidney disease research center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 5. Taleqani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 6. Department of Laboratory Sciences, Jondishapour University of Medical Sciences, Faculty of Paramedical Sciences, Ahvaz, Iran.
Abstract
BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD), a multisystem disorder, is the most prevalent type of hereditary kidney disease. Here, we aimed to evaluate methylation of the PKD1 gene (PKD1) promoter and its correlation with PKD1 expression in peripheral blood. METHODS: In this case-control study methylation of the PKD1 promoter was evaluated using methylation-sensitive high-resolution melt (MS-HRM) analysis. PKD1 expression was assessed by quantitative real-time PCR. The correlation was evaluated using the Pearson correlation test. RESULTS: Twenty subjects from both the patient and control groups (n= 40 for each) were methylated at the PKD1 promoter to various levels (18.9% in patients and 62.5% in controls). This difference was statistically significant (p< 0.0001). PKD1 expression in blood samples was significantly greater in ADPKD patients than in controls (p= 0.0081). Significant correlation was seen between PKD1 expression and its promoter methylation status in peripheral blood (r case= -0.5300, p= 0.0162, and r control = -0.6265, p= 0.0031). CONCLUSION: Methylation of the PKD1 promoter in ADPKD patients was inversely correlated with PKD1 expression.
BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD), a multisystem disorder, is the most prevalent type of hereditary kidney disease. Here, we aimed to evaluate methylation of the PKD1 gene (PKD1) promoter and its correlation with PKD1 expression in peripheral blood. METHODS: In this case-control study methylation of the PKD1 promoter was evaluated using methylation-sensitive high-resolution melt (MS-HRM) analysis. PKD1 expression was assessed by quantitative real-time PCR. The correlation was evaluated using the Pearson correlation test. RESULTS: Twenty subjects from both the patient and control groups (n= 40 for each) were methylated at the PKD1 promoter to various levels (18.9% in patients and 62.5% in controls). This difference was statistically significant (p< 0.0001). PKD1 expression in blood samples was significantly greater in ADPKD patients than in controls (p= 0.0081). Significant correlation was seen between PKD1 expression and its promoter methylation status in peripheral blood (r case= -0.5300, p= 0.0162, and r control = -0.6265, p= 0.0031). CONCLUSION: Methylation of the PKD1 promoter in ADPKD patients was inversely correlated with PKD1 expression.
Authors: G G Germino; D Weinstat-Saslow; H Himmelbauer; G A Gillespie; S Somlo; B Wirth; N Barton; K L Harris; A M Frischauf; S T Reeders Journal: Genomics Date: 1992-05 Impact factor: 5.736
Authors: Sarah A Bowden; Euan J Rodger; Michael Bates; Aniruddha Chatterjee; Michael R Eccles; Cherie Stayner Journal: Am J Nephrol Date: 2018-11-21 Impact factor: 3.754
Authors: Vichithra R B Liyanage; Jessica S Jarmasz; Nanditha Murugeshan; Marc R Del Bigio; Mojgan Rastegar; James R Davie Journal: Biology (Basel) Date: 2014-10-22
Authors: Sarah A Bowden; Euan J Rodger; Aniruddha Chatterjee; Michael R Eccles; Cherie Stayner Journal: Int J Mol Sci Date: 2021-12-11 Impact factor: 5.923